Regulation of CD93 cell surface expression by protein kinase C isoenzymes

Nobunao Ikewaki1, Jerzy K Kulski, Hidetoshi Inoko

  • 1Institute of Immunology, Kyushu University of Health and Welfare, Nobeoka, Miyazaki, Japan.

Microbiology and Immunology
|February 24, 2006
PubMed

Insights

Protein kinase C (PKC) isoenzymes regulate human CD93 (C1qRp) cell surface expression. Novel PKC inhibitor Rottlerin and classical PKC inhibitor Go6976 modulate CD93 levels in myeloid, NK-like, and endothelial cells.

Area of Science:

  • Immunology
  • Cell Biology
  • Biochemistry

Background:

  • Human CD93 (C1qRp) is expressed on myeloid cells, endothelial cells, platelets, and microglia.
  • CD93 is implicated in complement protein 1, q subcomponent (C1q)-mediated phagocytosis enhancement.
  • Intracellular mechanisms regulating cell surface CD93 expression remain largely undetermined.

Purpose of the Study:

  • To investigate the role of protein kinases in regulating CD93 cell surface expression.
  • To determine the effects of specific kinase inhibitors on CD93 expression in human cell lines.

Main Methods:

  • Utilized U937 (monocyte-like), KHYG-1 (NK-like), and HUV-EC-C (endothelial) cell lines.
  • Applied classical PKC (cPKC) inhibitor Go6976, novel PKC (nPKC) inhibitor Rottlerin, PKA inhibitor H-89, and PTK inhibitor herbimycin A.
  • Analyzed CD93 expression via flow cytometry and EIA using a specific monoclonal antibody (mAb).

Main Results:

  • nPKC inhibitor Rottlerin significantly down-regulated CD93 on U937 cells.
  • Go6976 down-regulated CD93 on KHYG-1 cells, while Rottlerin and Go6976 affected HUV-EC-C cells.
  • PKC activator PMA strongly up-regulated CD93 on all cell lines and induced cytokine production.

Conclusions:

  • Protein kinase C (PKC) isoenzymes play a crucial role in regulating CD93 expression.
  • Specific PKC pathways differentially control CD93 levels in various human cell types.
  • Findings elucidate molecular events governing CD93 cell surface presentation.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...